iCAD IncICAD
ICAD
About: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
Employees: 69
0
Funds holding %
of 7,363 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
21% more call options, than puts
Call options by funds: $57K | Put options by funds: $47K
10% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 10
9% more capital invested
Capital invested by funds: $8.15M [Q3] → $8.91M (+$765K) [Q4]
1.25% less ownership
Funds ownership: 19.61% [Q3] → 18.35% (-1.25%) [Q4]
4% less funds holding
Funds holding: 47 [Q3] → 45 (-2) [Q4]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Research analyst outlook
We haven’t received any recent analyst ratings for ICAD.
Financial journalist opinion
Based on 3 articles about ICAD published over the past 30 days
Neutral
GlobeNewsWire
6 days ago
iCAD and RamSoft Announce Partnership to Deliver ProFound® AI-Powered Mammography Solutions Across North America
NASHUA, N.H. and TORONTO, March 05, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and RamSoft®, a global leader in cloud-based RIS/PACS radiology solutions for imaging centers and providers, today announced a new strategic commercial preferred distributor and integration partnership across the US and Canada. With over 750 sites and thousands of healthcare providers worldwide utilizing RamSoft's solutions, this collaboration brings iCAD's ProFound AI® Breast Health Suite directly into imaging centers, enhancing workflow efficiency, increasing diagnostic confidence, and improving patient care, beginning within the platforms they already use.
Neutral
GlobeNewsWire
1 week ago
Koios Medical and iCAD Partner to Expand AI-Powered, Multi-Modality Breast Cancer Detection Solutions at ECR 2025
NASHUA, N.H. and CHICAGO, Feb. 26, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader in clinically proven AI-powered cancer detection solutions, and Koios Medical, a leader in AI-driven ultrasound cancer diagnosis, today announced a strategic reseller partnership to deliver a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD's ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis.
Neutral
GlobeNewsWire
3 weeks ago
iCAD To Showcase Five AI-Powered Research Presentations Advancing Breast Cancer Detection, Risk Evaluation, and Breast Arterial Calcification Assessment at ECR 2025
NASHUA, N.H., Feb. 19, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today announced that five clinical presentations and abstracts highlighting the Company's advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, 2025, in Vienna, Austria.
Neutral
GlobeNewsWire
1 month ago
iCAD Pre-Announces Estimated Q4 2024 Revenue
iCAD to Participate in the BTIG at Snowbird: 12 th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Neutral
Newsfile Corp
1 month ago
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
-New FDA Consultant is the former Director of the Division of Imaging, Diagnostics, and Software Reliability at the U.S Food and Drug Administration- -New Biostatistical Consultant is the former Deputy Director of the Biostatistics and Data Management Center of the American College of Radiology Imaging Network, an NIH-funded cooperative that conducts clinical trials to evaluate the use of diagnostic imaging and image-guided treatments for cancer, has decades of successful experience in design and analysis of clinical studies of medical imaging devices supporting U.S. Food and Drug Administration approval applications - -New Regulatory Consultant is the former VP of Regulatory Affairs, Clinical Affairs, and Quality Assurance for iCAD (NASDAQ: ICAD), a medical device manufacturer that offers computer-aided detection solutions for cancers including breast, and technology platforms including hardware and software for radiation therapy treatment- Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products utilizing innovative and emerging technologies for the more accurate screening, diagnoses, and treatment of breast cancers, is pleased to announce that Dr. Kyle J. Myers, Dr. Alicia Toledano, and Mr.
Neutral
GlobeNewsWire
2 months ago
SABCS 2024: New Research Assesses iCAD's Image Based AI-Risk, Detection, and Breast Arterial Calcifications (BAC) Assessment Across Diverse Populations
Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment Reveals Higher Prevalence of Breast Arterial Calcifications (BAC) in Breast Cancer Patients, Suggesting Potential Need for Cardiovascular Assessment Alongside Oncological Treatment
Neutral
GlobeNewsWire
3 months ago
CORRECTION – iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and ProFound Health Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
Neutral
GlobeNewsWire
3 months ago
iCAD Advances Fight Against Breast Cancer with FDA-cleared, Next-Generation AI Solutions and a Second-Read AI Partnership with Cascaid Health at RSNA 2024
ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025 ProFound Health, a Virtual Care Partnership with Cascaid Health, to Democratize Access to AI-Powered Mammography for All Patients – Launching Q1 2025
Neutral
Seeking Alpha
3 months ago
iCAD, Inc. (ICAD) Q3 2024 Earnings Call Transcript
iCAD, Inc. (NASDAQ:ICAD ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Rosalyn Christian - Investor Relations Dana Brown - President, Chief Executive Officer and Chairman Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallam Capital Yale Jen - Laidlaw & Company Operator Greetings. Welcome to the iCAD Incorporated Third Quarter 2024 Earnings Call.
Neutral
GlobeNewsWire
3 months ago
iCAD Reports Financial Results for Third Quarter Ended September 30, 2024
NASHUA, N.H., Nov. 13, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three and nine months ended September 30, 2024.
Charts implemented using Lightweight Charts™